Table 2.
Representative nanocrystal or nanoemulsion based formulations of poorly soluble drugs that are currently available commercially
| Formulation approach | Commercial name | Drug | Free drug solubility (μg/ml) | Major indication | Dosage form |
|---|---|---|---|---|---|
| Nanocrystal | Triglide® | Fenofibrate | 0.3 123 | Hypercholesterolemia | Tablet |
| Rapamune® | Sirolimus | 2.6 124 | Immunosuppresion | Tablet | |
| Emend® | Aprepitant | 3 - 7125 | Antiemetic | Capsule | |
| Tricor® | Fenofibrate | 0.3 | Hypercholesterolemia | Tablet | |
| Megace ES® | Megestrol | Antianorexia | Suspension (oral) | ||
| Invenga™ | Paliperidonepalmitate | 11 – 30 126 | Schizophrenia | Suspension (intramuscular) | |
|
| |||||
| Nanoemulsion | Estrasorb® | Estradiol | 2 127 | Menopausal vasomotor symptoms | Emulsion (topical) |
| Restasis® | Cyclosporine | 20 128 | Chronic dry eye | Emulsion (ophthalmic) | |
| SandimmunNeoral® | Cyclosporine | 20 128 | Prophylaxis of organ rejection following organ transplant | SMEDDS | |
| Norvir® | Ritonavir | 1 129 | HIV infection | SMEDDS | |
| Fortovase®* | Saquinavir | 29 130 | HIV infection | SMEDDS | |
SMEDDS: self-microemulsifying drug delivery system
*
Currently discontinued in the US